Anticoagulants in pregnancy

Obstetrical and Gynecological Survey

Volumn 61, Issue 1, 2006, Pages 59-69

  James, Andra H ^a,c   Abel, David E ^b   Brancazio, Leo R ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Northwest Perinatal Center   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANTITHROMBOCYTIC AGENT; CHONDROITIN SULFATE; CLOPIDOGREL; DALTEPARIN; DANAPAROID; DERMATAN SULFATE; DIPYRIDAMOLE; ENOXAPARIN; FIBRINOLYTIC AGENT; FONDAPARINUX; GLYCOSAMINOGLYCAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; RECOMBINANT HIRUDIN; RETEPLASE; REVIPARIN; STREPTOKINASE; TENECTEPLASE; TICLOPIDINE; TINZAPARIN; UROKINASE; WARFARIN;

ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGENITAL MALFORMATION; CONTRACEPTION; DELIVERY; DOSE RESPONSE; DRUG COST; DRUG HALF LIFE; DRUG MECHANISM; FETAL HEMORRHAGE; FETUS DISEASE; FETUS WASTAGE; GESTATION PERIOD; HEMATOMA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTELLIGENCE QUOTIENT; META ANALYSIS; NERVOUS SYSTEM INJURY; NEUROLOGIC DISEASE; NEWBORN DISEASE; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PREGNANCY; PUERPERIUM; REVIEW; SIDE EFFECT; SOLUTIO PLACENTAE; SPONTANEOUS ABORTION; STILLBIRTH; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT INDICATION; VERTEBRA FRACTURE;

ADULT; ANTICOAGULANTS; DRUG COSTS; FEMALE; HUMANS; PATIENT CARE PLANNING; PREGNANCY; PREGNANCY COMPLICATIONS; RISK FACTORS; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 30144438251     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ogx.0000193878.57208.ad     Document Type: Review

References (126)

1. Prevention of venous thrombosis and pulmonary embolism. NIH Consensus Development. JAMA 1986;256:744-749.
2. James A, Brancazio L, Jamison M, et al. Peripartum thromboembolism in the United States 2000-2001: incidence, mortality and risk factors. Am J Obstet Gynecol 2004;191:90S.
3. Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol 1996;16:742-748.
4. Conard J, Horellou MH, Van Dreden P, et al. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost 1990;63:319-320.
5. Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest 1982;14:127-141.
6. American College of Obstetricians and Gynecologists. Management of early recurrent pregnancy loss. ACOG Practice Bulletin no. 24. Washington, DC: American College of Obstetricians and Gynecologists, February 2001.
7. Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol 2002;101:6-14.
8. Lockwood CJ. Inherited thrombophilias in pregnant patients: detection and treatment paradigm. Obstet Gynecol 2002;99:333-341.
9. Brill-Edwards P, Ginsberg JS, Gent M, et al. Safety of with-holding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med 2000;343:1439-1444.
10. Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol 2003;101:1333-1344.
11. Gris JC, Mercier E, Quere I, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004;103:3695-3699.
12. Dickson B. Venous thrombosis: on the history of Virchow's Triad. University of Toronto Medical Journal 2004;81:166-171.
13. Gordon M. Maternal physiology in pregnancy. In: Gabbe S, Niebyl J, Simpson J, eds. Normal and Problem Pregnancies, 4th ed. New York: Churchill Livingstone, 2002:63-92.
14. Macklon NS, Greer IA, Bowman AW. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. BJOG 1997;104:191-197.
15. Whitty J, Dombrowski M. Respiratory diseases in pregnancy. In: Gabbe S, Niebyl J, Simpson J, eds. Normal and Problem Pregnancies, 4th ed. New York: Churchill Livingstone, 2002:1033-1064.
16. Danilenko-Dixon DR, Heit JA, Silverstein MD, et al. Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: a population-based, case-control study. Am J Obstet Gynecol 2001;184:104-110.
17. Sikovanyecz J, Orvos H, Pal A, et al. Leiden mutation, bed rest and infection: simultaneous triggers for maternal deep-vein thrombosis and neonatal intracranial hemorrhage? Fetal Diagn Ther 2004;19:275-277.
18. Kovacevich GJ, Gaich SA, Lavin JP, et al. The prevalence of thromboembolic events among women with extended bed rest prescribed as part of the treatment for premature labor or preterm premature rupture of membranes. Am J Obstet Gynecol 182:1089-1092.
19. Carr MH, Towers CV, Eastenson AR, et al. Prolonged bedrest during pregnancy: does the risk of deep vein thrombosis warrant the use of routine heparin prophylaxis? J Matern Fetal Med 1997;6:264-267.
20. Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 2003;16:153-168.
21. Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv 1999;54:265-271.
22. James AH, Tapson VF, Goldhaber SZ. Thrombosis during pregnancy and the postpartum period. Am J Obstet Gynecol 2005;193:216-219.
23. Ginsberg JS, Kowalchuk G, Hirsh J, et al. Heparin therapy during pregnancy. Risks to the fetus and mother. Arch Intern Med 1989;149:2233-2236.
24. Roberts D, Schwartz RS. Clotting and hemorrhage in the placenta - a delicate balance. N Engl J Med 2002;347:57-59.
25. Bates SM, Greer IA, Hirsh J, et al. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:627S-644S.
26. James A, Brancazio L, Ortel T. Thrombosis, thrombophilia and thromboprophylaxis in pregnancy. Clinical Advances in Hematology & Oncology 2005;3:187-197.
27. American College of Obstetricians and Gynecologists. Thromboembolism in pregnancy. 2000, ACOG Practice Bulletin no 19. Washington, DC: American College of Obstetrician and Gynecologists, August 2000.
28. Naimi TS, Lipscomb LE, Brewer RD, et al. Binge drinking in the preconception period and the risk of unintended pregnancy: implications for women and their children. Pediatrics 2003;111:1136-1141.
29. Organogenetic period: the fourth to eighth weeks. In: Moore K, ed. The Developing Human: Clinically Oriented Embryology, 6th ed. Philadelphia: WB Saunders Co, 1998:83-106.
30. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:204S-233S.
31. Iturbe-Alessio I, Fonseca MC, Mutchinik O, et al. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med 1986;315:1390-1393.
32. Sadler L, McCowan L, White H, et al. Pregnancy outcomes and cardiac complications in women with mechanical, bioprosthetic and homograft valves. BJOG 2000;107:245-253.
33. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000;160:191-196.
34. Nassar AH, Hobeika EM, Abd Essamad HM, et al. Pregnancy outcome in women with prosthetic heart valves. Am J Obstet Gynecol 2004;191:1009-1013.
35. Blickstein D, Blickstein I. The risk of fetal loss associated with warfarin anticoagulation. Int J Gynaecol Obstet 2002;78:221-225.
36. Srivastava AK, Gupta AK, Singh AV, et al. Effect of oral anticoagulant during pregnancy with prosthetic heart valve. Asian Cardiovasc Thorac Ann 2002;10:306-309.
37. Meschengieser SS, Fondevila CG, Santarelli MT, et al. Anticoagulation in pregnant women with mechanical heart valve prostheses. Heart 1999;82:23-26.
38. Cotrufo M, De Feo M, De Santo LS, et al. Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol 2002;99:35-40.
39. Chen WW, Chan CS, Lee PK, et al. Pregnancy in patients with prosthetic heart valves: an experience with 45 pregnancies. QJM 1982;51:358-365.
40. Wesseling J, Van Driel D, Heymans HS, et al. Coumarins during pregnancy: long-term effects on growth and development of school-age children. Thromb Haemost 2001;85:609-613.
41. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-698.
42. Flessa HC, Kapstrom AB, Glueck HI, et al. Placental transport of heparin. Am J Obstet Gynecol 1965;93:570-573.
43. Harenberg J, Schneider D, Heilmann L, et al. Lack of antifactor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women. Haemostasis 1993;23:314-320.
44. Schneider D, Heilmann L, Harenberg J. [Placental transfer of low-molecular weight heparin.] Geburtshilfe Frauenheilkd 1995;55:93-98.
45. Dahlman TC, Sjoberg HE, Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol 1994;170:1315-1320.
46. Barbour LA, Kick SD, Steiner JF, et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 1994;170:862-869.
47. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993;168:1265-1270.
48. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335.
49. Fausett MB, Vogtlander M, Lee RM, et al. Heparin-induced thrombocytopenia is rare in pregnancy. Am J Obstet Gynecol 2001;185:148-152.
50. Dimitrakakis C, Papageorgiou P, Papageorgiou I, et al. Absence of transplacental passage of the low molecular weight heparin enoxaparin. Haemostasis 2000;30:243-248.
51. Melissari E, Parker CJ, Wilson NV, et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost 1992;68:652-656.
52. Lepercq J, Conard J, Borel-Derlon A, et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG 2001;108:1134-1140.
53. Ibbotson T, Perry CM. Danaparoid: a review of its use in thromboembolic and coagulation disorders. Drugs 2002;62:2283-2314.
54. Lindhoff-Last E, Bauersachs R. Heparin-induced thrombocytopenia- alternative anticoagulation in pregnancy and lactation. Semin Thromb Hemost 2002;28:439-446.
55. Dager WE, White RH. Treatment of heparin-induced thrombocytopenia. Ann Pharmacother 2002;36:489-503.
56. de Saint-Blanquat L, Simon L, Toubas MF, et al. [Treatment with danaparoid during pregnancy for a woman with a cutenous allergy to low-molecular-weight heparin.] Ann Fr Anesth Reanim 2000;19:751-754.
57. Myers B, Westby J, Strong J. Prophylactic use of danaparoid in high-risk pregnancy with heparin-induced thrombocytopaenia-positive skin reaction. Blood Coagul Fibrinolysis 2003;14:485-487.
58. Taylor AA. Successful use of heparinoids in a pregnancy complicated by allergy to heparin. BJOG 2001;108:1011-1012.
59. Macchi L, Sarfati R, Guicheteau M, et al. Thromboembolic prophylaxis with danaparoid (Orgaran) in a high-thrombosis-risk pregnant woman with a history of heparin-induced thrombocytopenia (HIT) and Widal's disease. Clin Appl Thromb Hemost 2000;6:187-189.
60. Woo YL, Allard S, Cohen H, et al. Danaparoid thromboprophylaxis in pregnant women with heparin-induced thrombocytopenia. BJOG 2002;109:466-468.
61. Gill J, Kovacs MJ. Successful use of danaparoid in treatment of heparin-induced thrombocytopenia during twin pregnancy. Obstet Gynecol 1997;90:648-650.
62. Aijaz A, Nelson J, Naseer N. Management of heparin allergy in pregnancy. Am J Hematol 2001;67:268-269.
63. Huhle G, Geberth M, Hoffmann U, et al. Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin. Gynecol Obstet Invest 2000;49:67-69.
64. Markwardt F, Fink G, Kaiser B, et al. Pharmacological survey of recombinant hirudin. Pharmazie 1988;43:202-207.
65. Lagrange F, Brun JL, Vergnes MC, et al. Fondaparinux sodium does not cross the placental barrier: study using the in-vitro human dually perfused cotyledon model. Clin Pharmacokinet 2002;41:47-49.
66. Lagrange F, Vergnes C, Brun JL, et al. Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro. Thromb Haemost 2002;87:831-835.
67. Dempfle CE. Minor transplacental passage of fondaparinux in vivo. N Engl J Med 2004;350:1914-1915.
68. Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:2345-2645.
69. Duley L, Henderson-Smart D, Knight M, et al. Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. BMJ 2001;322:329-333.
70. Coomarasamy A, Braunholtz D, Song F, et al. Individualising use of aspirin to prevent pre-eclampsia: a framework for clinical decision making. BJOG 2003;110:882-888.
71. Rowan JA, McCowan LM, Raudkivi PJ, et al. Enoxaparin treatment in women with mechanical heart valves during pregnancy. Am J Obstet Gynecol 2001;185:633-637.
72. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002;100:408-413.
73. Pattison NS, Chamley LW, Birdsall M, et al. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol 2000;183:1008-1012.
74. Klinzing P, Markert UR, Liesaus K, et al. Case report: successful pregnancy and delivery after myocardial infarction and essential thrombocythemia treated with clopidrogel. Clin Exp Obstet Gynecol 2001;28:215-216.
75. Martin M, Romero E, Moris C. [Acute myocardial infarction during pregnancy. Treatment with clopidogrel.] Med Clin (Barc) 2003;121:278-279.
76. Ueno M, Masuda H, Nakamura K, et al. Antiplatelet therapy for a pregnant woman with a mechanical aortic valve: report of a case. Surg Today 2001;31:1002-1004.
77. Sebastian C, Scherlag M, Kugelmass A, et al. Primary stent implantation for acute myocardial infarction during pregnancy: use of abciximab, ticlopidine, and aspirin. Cathet Cardiovasc Diagn 1998;45:275-279.
78. Miller RK, Mace K, Polliotti B, et al. Marginal transfer of ReoPro (Abciximab) compared with immunoglobulin G (F105), inulin and water in the perfused human placenta in vitro. Placenta 2003;24:727-738.
79. Ahearn GS, Hadjiliadis D, Govert JA, et al. Massive pulmonary embolism during pregnancy successfully treated with recombinant tissue plasminogen activator: a case report and review of treatment options. Arch Intern Med 2002;162:1221-1227.
80. Mazeika PK, Oakley CM. Massive pulmonary embolism in pregnancy treated with streptokinase and percutaneous catheter fragmentation. Eur Heart J 1994;15:1281-1283.
81. Krishnamurthy P, Martin CB, Kay HH, et al. Catheter-directed thrombolysis for thromboembolic disease during pregnancy: a viable option. J Matern Fetal Med 1999;8:24-27.
82. Kramer WB, Belfort M, Saade GR, et al. Successful urokinase treatment of massive pulmonary embolism in pregnancy. Obstet Gynecol 1995;86:660-662.
83. Walther C, Koestering H. [Therapeutic thrombolysis in the ninth week of pregnancy.] Ger Med Mon 1969;14:332.
84. Schumacher B, Belfort MA, Card RJ. Successful treatment of acute myocardial infarction during pregnancy with tissue plasminogen activator. Am J Obstet Gynecol 1997;176:716-719.
85. Henrich W, Schmider A, Henrich M, et al. Acute iliac vein thrombosis in pregnancy treated successfully by streptokinase lysis: a case report. J Perinat Med 2001;29:155-157.
86. Patterson DE, Raviola CA, D'Orazio EA, et al. Thrombolytic and endovascular treatment of peripartum iliac vein thrombosis: a case report. J Vasc Surg 1996;24:1030-1033.
87. Niwa J, Ohyama H, Matumura S, et al. Treatment of acute superior sagittal sinus thrombosis by t-PA infusion via venography - direct thrombolytic therapy in the acute phase. Surg Neurol 1998;49:425-429.
88. Chow K, Gobin YP, Saver J, et al. Endovascular treatment of durai sinus thrombosis with rheolytic thrombectomy and intra-arterial thrombolysis. Stroke 2000;31:1420-1425.
89. Usta IM, Abdallah M, El-Hajj M, et al. Massive subchorionic hematomas following thrombolytic therapy in pregnancy. Obstet Gynecol 2004;103:1079-1082.
90. Fleyfel M, Bourzoufi K, Huin G, et al. Recombinant tissue type plasminogen activator treatment of thrombosed mitral valve prosthesis during pregnancy. Can J Anaesth 1997;44:735-738.
91. Turrentine MA, Braems G, Ramirez MM. Use of thrombolytics for the treatment of thromboembolic disease during pregnancy. Obstet Gynecol Surv 1995;50:534-541.
92. Stewart JA, Hamilton PJ, Murdoch AP. Thromboembolic disease associated with ovarian stimulation and assisted conception techniques. Hum Reprod 1997;12:2167-2173.
93. Barbour LA, Smith JM, Marlar RA. Heparin levels to guide thromboembolism prophylaxis during pregnancy. Am J Obstet Gynecol 1995;173:1869-1873.
94. Brancazio LR, Roperti KA, Stierer R, et al. Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. Am J Obstet Gynecol 1995;173:1240-1245.
95. Casele HL, Laifer SA, Woelkers DA, et al. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999;181:1113-1117.
96. Laifer SA, Casele HL. Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. BJOG 1999;106:614-615.
97. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:311S-337S.
98. McCrae KR, Bussel JB, Mannucci PM, et al. Platelets: an update on diagnosis and management of thrombocytopenic disorders. Hematology Am Soc Hematol Educ Program 2001;282-305.
99. Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 2005;127:35S-45S.
100. Horlocker TT. Low molecular weight heparin and neuraxial anesthesia. Thromb Res 2001;101:141-154.
101. Baker WH, Mahler DK, Foldes MS, et al. Pneumatic compression devices for prophylaxis of deep venous thrombosis (DVT). Am Surg 1986;52:371-373.
102. Orme ML, Lewis PJ, de Swiet M, et al. May mothers given warfarin breast-feed their infants? BMJ 1977;1:1564-1565.
103. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776-789.
104. Beller FK, Ebert C. Effects of oral contraceptives on blood coagulation. A review. Obstet Gynecol Surv 1985;40:425-436.
105. Blomback M, Landgren BM, Stiernholm Y, et al. The effect of progesterone on the haemostatic mechanism. Thromb Haemost 1997;77:105-108.
106. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998;57:315-324.
107. Stewart A, Cummins C, Gold L, et al. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. BJOG 2001;108:74-86.
108. Vural KM, Ozatik MA, Uncu H, et al. Pregnancy after mechanical mitral valve replacement. J Heart Valve Dis 2003;12:370-376.
109. Sephton V, Farquharson RG, Topping J, et al. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. Obstet Gynecol 1307;101:1307-1311.
110. Blomback M, Bremme K, Hellgren M, et al. A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. Blood Coagul Fibrinolysis 1998;9:343-350.
111. Sanson BJ, Lensing AW, Prins MH, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999;81:668-672.
112. Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000;111:733-744.
113. Markwardt F. Hirudin as alternative anticoagulant - a historical review. Semin Thromb Hemost 2002;28:405-414.
114. Markwardt F, Nowak G, Sturzebecher J. Clinical pharmacology of recombinant hirudin. Haemostasis 1991;1:133-136.
115. Zoldhelyi P, Webster MW, Fuster V, et al. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters. Circulation 1993;88:2015-2022.
116. Parody R, Oliver A, Souto JC, et al. Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica 2003;88:ECR32.
117. Donat F, Duret JP, Santoni A, et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002;41:1-9.
118. Bauer KA. Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm 2001;58(suppl 2):S14-17.
119. Feuring M, Haseroth K, Janson CP, et al. Inhibition of platelet aggregation after intake of acetylsalicylic acid detected by a platelet function analyzer (PFA-100). Int J Clin Pharmacol Ther 1999;37:584-588.
120. Coomarasamy A, Honest H, Papaioannou S, et al. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol 2003;101:1319-1332.
121. DiPerri T, Pasini FL, Frigerio C, et al. Pharmacodynamics of ticlopidine in man in relation to plasma and blood cell concentration. Eur J Clin Pharmacol 1991;41:429-434.
122. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001;103:2572-2578.
123. Kottke-Marchant K, Powers JB, Brooks L, et al. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100). Clin Appl Thromb Hemost 1999;5:122-130.
124. Madan M, Berkowitz SD, Christie DJ, et al. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. Am Heart J 2001;141:226-233.
125. Grau AJ, Reiners S, Lichy C, et al. Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. Stroke 2003;34:849-854. Epub Mar 13, 2003.
126. Menon V, Harrington RA, Hochman JS, et al. Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:5495-5755.